A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
Phase 2
60
about 1.8 years
18+
14 sites in CO, IL, MD +7
What this study is about
This trial is testing a treatment with fruquintinib and FOLFIRI in people with metastatic colorectal cancer. The goal is to see if this combination is effective and safe.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
- 2.Take fruquintinib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), chemotherapy (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), irinotecan, Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions), fruquintinib
oral (Oral Capsule), injection (Injection)
Primary: Progression-Free Survival (PFS) rate at 6 months
Secondary: Disease control response rate (DCR), Duration of response (DoR), Number of participants with treatment emergent adverse events, Overall Response Rate (ORR), Overall Survival (OS)
Oncology